U.S. pharma big copyright scrapped two experimental weight loss products very last year—a the moment-day-to-day capsule, lotiglipron, as a result of elevated liver enzymes and also a twice-daily tablet, danuglipron, as a consequence of robust Negative effects—but CEO Albert Bourla has said the company is decided to “play and earn” inside th